JPWO2021188769A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021188769A5 JPWO2021188769A5 JP2022556522A JP2022556522A JPWO2021188769A5 JP WO2021188769 A5 JPWO2021188769 A5 JP WO2021188769A5 JP 2022556522 A JP2022556522 A JP 2022556522A JP 2022556522 A JP2022556522 A JP 2022556522A JP WO2021188769 A5 JPWO2021188769 A5 JP WO2021188769A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- alkoxy
- haloalkyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 147
- 125000003545 alkoxy group Chemical group 0.000 claims description 119
- 229910052736 halogen Inorganic materials 0.000 claims description 86
- 150000002367 halogens Chemical class 0.000 claims description 86
- 150000001875 compounds Chemical class 0.000 claims description 72
- 150000003839 salts Chemical class 0.000 claims description 62
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 57
- 239000012453 solvate Substances 0.000 claims description 44
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 43
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 43
- 229910052799 carbon Inorganic materials 0.000 claims description 43
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 39
- 125000000623 heterocyclic group Chemical group 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 21
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000004043 oxo group Chemical group O=* 0.000 claims description 13
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 12
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 11
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 9
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 8
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 8
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 8
- 150000001721 carbon Chemical group 0.000 claims description 8
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- -1 C1-4alkoxyC1-4alkyl Chemical group 0.000 claims description 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 10
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 229910003827 NRaRb Inorganic materials 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 11
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 11
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 11
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 6
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 6
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 102000008096 B7-H1 Antigen Human genes 0.000 description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 4
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 229940127272 CD73 inhibitor Drugs 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000033133 Testicular seminomatous germ cell tumor Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000024662 testicular seminoma Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024065054A JP2024096875A (ja) | 2020-03-19 | 2024-04-15 | Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991952P | 2020-03-19 | 2020-03-19 | |
| US62/991,952 | 2020-03-19 | ||
| US202063120875P | 2020-12-03 | 2020-12-03 | |
| US63/120,875 | 2020-12-03 | ||
| PCT/US2021/022912 WO2021188769A1 (en) | 2020-03-19 | 2021-03-18 | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024065054A Division JP2024096875A (ja) | 2020-03-19 | 2024-04-15 | Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518286A JP2023518286A (ja) | 2023-04-28 |
| JPWO2021188769A5 true JPWO2021188769A5 (da) | 2023-07-12 |
| JP7474861B2 JP7474861B2 (ja) | 2024-04-25 |
Family
ID=75660301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556522A Active JP7474861B2 (ja) | 2020-03-19 | 2021-03-18 | Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物 |
| JP2024065054A Pending JP2024096875A (ja) | 2020-03-19 | 2024-04-15 | Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024065054A Pending JP2024096875A (ja) | 2020-03-19 | 2024-04-15 | Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11407712B2 (da) |
| EP (1) | EP4121409A1 (da) |
| JP (2) | JP7474861B2 (da) |
| KR (1) | KR20220155593A (da) |
| CN (1) | CN115298165B (da) |
| AU (1) | AU2021240068A1 (da) |
| BR (1) | BR112022018600A2 (da) |
| CA (1) | CA3173831A1 (da) |
| CL (1) | CL2022002515A1 (da) |
| CO (1) | CO2022013274A2 (da) |
| CR (1) | CR20220470A (da) |
| DO (1) | DOP2022000194A (da) |
| IL (1) | IL295569A (da) |
| MX (1) | MX2022011534A (da) |
| PE (1) | PE20230673A1 (da) |
| TW (1) | TW202144325A (da) |
| WO (1) | WO2021188769A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20230673A1 (es) | 2020-03-19 | 2023-04-20 | Arcus Biosciences Inc | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa |
| WO2022086882A1 (en) | 2020-10-21 | 2022-04-28 | Nikang Therapeutics, Inc. | Diagnostic and therapeutic methods for treatment of cancer with a hif-2(alpha) inhibitor |
| CN117337288A (zh) | 2021-05-21 | 2024-01-02 | 艾库斯生物科学有限公司 | Axl抑制剂化合物 |
| TW202313602A (zh) | 2021-05-21 | 2023-04-01 | 美商阿克思生物科學有限公司 | Axl化合物 |
| AU2022376961A1 (en) | 2021-10-29 | 2024-05-16 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| US20240124490A1 (en) | 2022-07-15 | 2024-04-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202421150A (zh) | 2022-09-14 | 2024-06-01 | 美商阿克思生物科學有限公司 | 艾魯美冷之分散體 |
| CN117776987A (zh) * | 2022-09-27 | 2024-03-29 | 苏州阿尔脉生物科技有限公司 | 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途 |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| US20240180947A1 (en) | 2022-10-20 | 2024-06-06 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| BR0210149A (pt) | 2001-05-09 | 2004-06-29 | Newbiotics Inc | Pródrogas ativadas por deformilase de peptìdeo |
| SI1644336T1 (sl) * | 2003-06-06 | 2011-06-30 | Fibrogen Inc | Heteroarilne spojine, ki vsebujejo duĺ ik in njihova uporaba pri zviĺ anju endogenega eritropoetina |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| DK2343320T3 (da) | 2005-03-25 | 2018-01-29 | Gitr Inc | Anti-gitr-antistoffer og anvendelser deraf |
| WO2007005874A2 (en) | 2005-07-01 | 2007-01-11 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US8314234B2 (en) | 2006-09-25 | 2012-11-20 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
| GB0704407D0 (en) | 2007-03-07 | 2007-04-18 | Glaxo Group Ltd | Compounds |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| JP5932217B2 (ja) | 2007-07-12 | 2016-06-08 | ジーアイティーアール， インコーポレイテッド | Ｇｉｔｒ結合分子を使用する併用療法 |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AU2009210570B2 (en) | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| PT4209510T (pt) | 2008-12-09 | 2024-04-02 | Hoffmann La Roche | Anticorpos anti-pm-l1 e a sua utilização para a melhoria do funcionamento das células t |
| CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
| CA2780692C (en) | 2009-12-10 | 2018-09-11 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| EA030226B1 (ru) | 2010-03-04 | 2018-07-31 | Макродженикс, Инк. | Антитела, реактивные к b7-h3, их иммунологически активные фрагменты и их применения |
| MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| US9221910B2 (en) | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| PL2566517T3 (pl) | 2010-05-04 | 2019-04-30 | Five Prime Therapeutics Inc | Przeciwciała wiążące csf1r |
| CA2810359C (en) | 2010-09-09 | 2021-06-22 | Pfizer Inc. | 4-1bb binding molecules |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| EP3763741A1 (en) | 2011-11-28 | 2021-01-13 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| JP6242804B2 (ja) | 2011-12-15 | 2017-12-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| CA2861122A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| BR112014028013A2 (pt) | 2012-05-11 | 2018-02-27 | Five Prime Therapeutics Inc | métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea |
| CN102786512A (zh) | 2012-05-31 | 2012-11-21 | 中国人民解放军军事医学科学院毒物药物研究所 | N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| EP3679949A1 (en) | 2012-08-31 | 2020-07-15 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| WO2014078479A2 (en) | 2012-11-14 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT) |
| ES2608305T3 (es) | 2013-08-13 | 2017-04-07 | Philip Morris Products S.A. | Artículo para fumar que comprende una fuente de calor combustible ciega |
| SI3417851T1 (sl) | 2013-09-09 | 2020-11-30 | Peloton Therapeutics, Inc. | Aril etri in njihova uporaba |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| CA2931085C (en) | 2013-12-16 | 2021-10-19 | Peloton Therapeutics, Inc. | Cyclic sulfone and sulfoximine analogs and uses thereof |
| EP3203991A4 (en) | 2014-10-10 | 2018-06-20 | The Board of Regents of The University of Texas System | Hif-2 inhibitors for treating iron overload disorders |
| WO2016145236A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Hif-2-alpha inhibitor polymorphs |
| US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
| US10155726B2 (en) | 2015-03-11 | 2018-12-18 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
| WO2016145032A1 (en) * | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| US9796697B2 (en) | 2015-06-12 | 2017-10-24 | Peloton Therapeutics, Inc. | Tricyclic inhibitors of HIF-2-alpha and uses thereof |
| US20190048421A1 (en) | 2015-09-21 | 2019-02-14 | The Board Of Regents Of The University Of Texas System | Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof |
| HUE063388T2 (hu) | 2016-01-08 | 2024-01-28 | Arcus Biosciences Inc | Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása |
| WO2018031680A1 (en) | 2016-08-10 | 2018-02-15 | Fronthera U.S. Pharmaceuticals Llc | Novel compounds, uses and methods for their preparation |
| JP7184761B2 (ja) | 2016-10-03 | 2022-12-06 | アーカス バイオサイエンシズ インコーポレイティド | アデノシン５’－ヌクレオチダーゼの阻害剤 |
| EP3541396A4 (en) | 2016-11-18 | 2020-07-22 | Arcus Biosciences, Inc. | CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS |
| HRP20231157T1 (hr) | 2017-01-20 | 2024-01-05 | Arcus Biosciences, Inc. | Azolopirimidin za liječenje poremećaja povezanih s rakom |
| ES2953349T3 (es) | 2017-05-05 | 2023-11-10 | Arcus Biosciences Inc | Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer |
| JP7189155B2 (ja) | 2017-05-17 | 2022-12-13 | アーカス バイオサイエンシズ インコーポレイティド | 癌関連障害の治療のためのキナゾリン－ピラゾール誘導体 |
| FR3071726B1 (fr) * | 2017-09-29 | 2020-09-04 | Univ Paris Sud | Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| WO2019191227A1 (en) | 2018-03-28 | 2019-10-03 | Peloton Therapeutics, Inc. | Methods of reducing inflammation of the digestive system with inhibitors of hif-2-alpha |
| EP3829581B1 (en) | 2018-07-27 | 2024-04-03 | Arcus Biosciences, Inc. | Pyridone a2r antagonists |
| WO2020046813A1 (en) | 2018-08-27 | 2020-03-05 | Arcus Biosciences, Inc. | Cd73 inhibitors |
| US20220054451A1 (en) | 2018-09-11 | 2022-02-24 | Nikang Therapeutics, Inc. | 2,3-DIHYDROBENZO[b]THIOPHENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS |
| US12077506B2 (en) | 2018-10-17 | 2024-09-03 | Nikang Therapeutics, Inc. | Indane derivatives as hypoxia inducible factor-2(α) inhibitors |
| US20210387946A1 (en) | 2018-10-30 | 2021-12-16 | Peloton Therapeutics Inc. | Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof |
| JP7461350B2 (ja) | 2018-11-16 | 2024-04-03 | アーカス バイオサイエンシーズ インコーポレイテッド | Ａｒｇ１及び／又はａｒｇ２の阻害剤 |
| CN109776607B (zh) | 2019-02-21 | 2021-06-04 | 青岛海洋生物医药研究院 | 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用 |
| MX2021012549A (es) | 2019-04-18 | 2022-01-18 | Nikang Therapeutics Inc | Derivados de tetrahidro-1h-ciclopenta[cd]indeno como inhibidores del factor inducible por hipoxia-2(alfa). |
| US20220274914A1 (en) | 2019-07-22 | 2022-09-01 | Nikang Therapeutics, Inc. | Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitors |
| IL293305A (en) | 2019-11-26 | 2022-07-01 | Merck Patent Gmbh | The history of thiofan, their preparation and their use |
| WO2021113436A1 (en) | 2019-12-04 | 2021-06-10 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha |
| CN111303053B (zh) | 2020-03-16 | 2023-01-17 | 中国海洋大学 | 环戊并[d]嘧啶类化合物及其药学上可接受的盐、溶剂合物或者前药以及应用 |
| PE20230673A1 (es) | 2020-03-19 | 2023-04-20 | Arcus Biosciences Inc | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa |
-
2021
- 2021-03-18 PE PE2022001986A patent/PE20230673A1/es unknown
- 2021-03-18 CN CN202180022951.7A patent/CN115298165B/zh active Active
- 2021-03-18 CR CR20220470A patent/CR20220470A/es unknown
- 2021-03-18 WO PCT/US2021/022912 patent/WO2021188769A1/en active Application Filing
- 2021-03-18 JP JP2022556522A patent/JP7474861B2/ja active Active
- 2021-03-18 TW TW110109681A patent/TW202144325A/zh unknown
- 2021-03-18 IL IL295569A patent/IL295569A/en unknown
- 2021-03-18 CA CA3173831A patent/CA3173831A1/en active Pending
- 2021-03-18 MX MX2022011534A patent/MX2022011534A/es unknown
- 2021-03-18 AU AU2021240068A patent/AU2021240068A1/en active Pending
- 2021-03-18 US US17/205,273 patent/US11407712B2/en active Active
- 2021-03-18 BR BR112022018600A patent/BR112022018600A2/pt unknown
- 2021-03-18 EP EP21721245.5A patent/EP4121409A1/en active Pending
- 2021-03-18 KR KR1020227035900A patent/KR20220155593A/ko active Search and Examination
-
2022
- 2022-06-08 US US17/835,559 patent/US11787762B2/en active Active
- 2022-09-14 CL CL2022002515A patent/CL2022002515A1/es unknown
- 2022-09-16 CO CONC2022/0013274A patent/CO2022013274A2/es unknown
- 2022-09-16 DO DO2022000194A patent/DOP2022000194A/es unknown
-
2024
- 2024-04-15 JP JP2024065054A patent/JP2024096875A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295569A (en) | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha | |
| JP2020111618A5 (da) | ||
| JP2019529500A5 (da) | ||
| CA2698018C (en) | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | |
| JPWO2021188769A5 (da) | ||
| JP2019501223A5 (da) | ||
| JP2017537080A5 (da) | ||
| JP2010539095A5 (da) | ||
| JP2016534134A5 (da) | ||
| JP2005524631A5 (da) | ||
| JP2017525753A5 (da) | ||
| US20020016328A1 (en) | Corticotropin releasing factor antagonists | |
| JP2017538678A5 (da) | ||
| JP2021529814A (ja) | 化学化合物 | |
| JP2019529444A5 (da) | ||
| JP2016523973A5 (da) | ||
| JP2012505235A5 (da) | ||
| JP2020519664A5 (da) | ||
| CA2491895A1 (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases | |
| JP2011511095A5 (da) | ||
| EA029027B1 (ru) | Замещенные имидазопиридазины | |
| JP2009515984A5 (da) | ||
| JP7475402B2 (ja) | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 | |
| JPWO2018204661A5 (da) | ||
| Lee et al. | Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl) propanamides as potent TRPV1 antagonists |